Diagnosis and Treatment > Signs and Symptoms

You are looking at 1 - 2 of 2 items for :

  • Prognathism x
  • Face - coarse features x
Clear All
Syed Ali Imran Division of Endocrinology and Metabolism, Dalhousie University, Halifax, Nova Scotia, Canada

Search for other papers by Syed Ali Imran in
Google Scholar
PubMed
Close
,
Khaled A Aldahmani Division of Endocrinology, Tawam Hospial, Al-Ain, UAE

Search for other papers by Khaled A Aldahmani in
Google Scholar
PubMed
Close
,
Lynette Penney Department of Pediatrics, Tawam Hospial, Al-Ain, UAE

Search for other papers by Lynette Penney in
Google Scholar
PubMed
Close
,
Sidney E Croul Department of Pathology, Tawam Hospial, Al-Ain, UAE

Search for other papers by Sidney E Croul in
Google Scholar
PubMed
Close
,
David B Clarke Department of Neurosurgery, Dalhousie University, Halifax, Nova Scotia, Canada

Search for other papers by David B Clarke in
Google Scholar
PubMed
Close
,
David M Collier Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by David M Collier in
Google Scholar
PubMed
Close
,
Donato Iacovazzo Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by Donato Iacovazzo in
Google Scholar
PubMed
Close
, and
Márta Korbonits Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Close

Summary

Early-onset acromegaly causing gigantism is often associated with aryl-hydrocarbon-interacting receptor protein (AIP) mutation, especially if there is a positive family history. A15y male presented with tiredness and visual problems. He was 201 cm tall with a span of 217 cm. He had typical facial features of acromegaly, elevated IGF-1, secondary hypogonadism and a large macroadenoma. His paternal aunt had a history of acromegaly presenting at the age of 35 years. Following transsphenoidal surgery, his IGF-1 normalized and clinical symptoms improved. He was found to have a novel AIP mutation destroying the stop codon c.991T>C; p.*331R. Unexpectedly, his father and paternal aunt were negative for this mutation while his mother and older sister were unaffected carriers, suggesting that his aunt represents a phenocopy.

Learning points:

  • Typical presentation for a patient with AIP mutation with excess growth and eunuchoid proportions.

  • Unusual, previously not described AIP variant with loss of the stop codon.

  • Phenocopy may occur in families with a disease-causing germline mutation.

Open access
Noor Rafhati Adyani Abdullah Endocrinology Unit, Department of Medicine, Putrajaya Hospital, Putrajaya, Malaysia

Search for other papers by Noor Rafhati Adyani Abdullah in
Google Scholar
PubMed
Close
,
Wong Lok Chin Jason Department of Medicine, National University of Malaysia Medical Centre, Kuala Lumpur, Malaysia

Search for other papers by Wong Lok Chin Jason in
Google Scholar
PubMed
Close
, and
Azraai Bahari Nasruddin Endocrinology Unit, Department of Medicine, Putrajaya Hospital, Putrajaya, Malaysia

Search for other papers by Azraai Bahari Nasruddin in
Google Scholar
PubMed
Close

Summary

Pachydermoperiostosis is a very rare osteoarthrodermopathic disorder whose clinical and radiographic presentations may mimic those of acromegaly. In the evaluation of patients with acromegaloid appearances, pachydermoperiostosis should be considered as a differential diagnosis. In this article, we report a 17-year-old boy who presented with 2-year history of acral enlargement and facial appearance changes associated with joint pain and excessive sweating. He had been investigated extensively for acromegaly, and the final diagnosis was pachydermoperiostosis.

Learning points

  • There is a broad range of differential diagnosis for acromegaloid features such as acromegaly, pseudoacromegaly with severe insulin resistance, Marfan’s syndrome, McCune–Albright and a rare condition called pachydermoperiostosis.

  • Once a patient is suspected to have acromegaly, the first step is biochemical testing to confirm the clinical diagnosis, followed by radiologic testing to determine the cause of the excess growth hormone (GH) secretion. The cause is a somatotroph adenoma of the pituitary in over 95 percent of cases.

  • The first step is measurement of a serum insulin-like growth factor 1 (IGF1). A normal serum IGF1 concentration is strong evidence that the patient does not have acromegaly.

  • If the serum IGF1 concentration is high (or equivocal), serum GH should be measured after oral glucose administration. Inadequate suppression of GH after a glucose load confirms the diagnosis of acromegaly.

  • Once the presence of excess GH secretion is confirmed, the next step is pituitary magnetic resonance imaging (MRI).

  • Atypical presentation warrants revision of the diagnosis. This patient presented with clubbing with no gigantism, which is expected in adolescent acromegalics as the growth spurt and epiphyseal plate closure have not taken place yet.

Open access